Corporate Overview

A FULLY INTEGRATED BIOPHARMACEUTICAL COMPANY WITH A ROBUST IMMUNO-ONCOLOGY PIPELINE AND PROVEN COMMERCIAL CAPABILITIES ACROSS MULTIPLE THERAPEUTIC AREAS INCLUDING ONCOLOGY, OPHTHALMOLOGY, AND IMMUNOLOGY.

Coherus is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. We are building a leading oncology company backed by in-house expertise and an established infrastructure from our diversified portfolio of FDA-approved biosimilar products.

Coherus’ immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust immunologic response and enhance outcomes for patients with cancer. The foundational therapy in our immuno-oncology pipeline is LOQTORZI, a next-generation PD-1 inhibitor. Casdozokitug is a novel anti-IL-27 antibody currently being evaluated in two on-going clinical studies: a Phase 1/2 study in advanced solid tumors and a Phase 2 study in hepatocellular carcinoma. CHS-114 is a highly selective, competitively positioned, ADCC-enhanced anti-CCR8 antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors.

Coherus’ earlier-stage immuno-oncology pipeline includes CHS-1000, a proprietary ILT4 antibody, and other immuno-therapies targeting novel pathways.

Coherus markets LOQTORZI™ (toripalimab-tpzi), a next-generation PD-1 inhibitor, UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®, CIMERLI® (ranibizumab-eqrn), a biosimilar of Lucentis®, and YUSIMRY™ (adalimumab-aqvh), a biosimilar of Humira®.

Coherus is headquartered in the heart of California’s Silicon Valley and composed of a team of industry veterans with decades of experience pioneering biologics companies.